Glenmark Pharmaceuticals (GLENMARK) Stock Overview
Research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
GLENMARK Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Glenmark Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,317.90 |
| 52 Week High | ₹2,474.00 |
| 52 Week Low | ₹1,792.60 |
| Beta | 0.25 |
| 1 Month Change | 5.36% |
| 3 Month Change | 2.60% |
| 1 Year Change | 19.65% |
| 3 Year Change | 213.46% |
| 5 Year Change | 348.68% |
| Change since IPO | 8,447.64% |
Recent News & Updates
Analysis Article • Aug 05
Analysts Have Made A Financial Statement On Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) First-Quarter Report
As you might know, Glenmark Pharmaceuticals Limited ( NSE:GLENMARK ) recently reported its quarterly numbers. It was a...
Narrative Update • Jul 07
GLENMARK: Updated US Portfolio And Margin Assumptions Will Shape Future Earnings
Analysts have raised their fair value estimate for Glenmark Pharmaceuticals from about ₹1,531.86 to roughly ₹2,116.59, citing updated assumptions on revenue growth, profit margin, discount rate and future P/E that they believe better reflect the stock's current risk and earnings profile. What’s in the News for Glenmark Pharmaceuticals Glenmark Pharmaceuticals held an Analyst and Investor Day, providing the market with an updated view of its business priorities, capital allocation plans, and assumptions that can influence how investors assess the stock.Recent updates
Analysis Article • Aug 05
Analysts Have Made A Financial Statement On Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) First-Quarter Report
As you might know, Glenmark Pharmaceuticals Limited ( NSE:GLENMARK ) recently reported its quarterly numbers. It was a...Narrative Update • Jul 07
GLENMARK: Updated US Portfolio And Margin Assumptions Will Shape Future Earnings
Analysts have raised their fair value estimate for Glenmark Pharmaceuticals from about ₹1,531.86 to roughly ₹2,116.59, citing updated assumptions on revenue growth, profit margin, discount rate and future P/E that they believe better reflect the stock's current risk and earnings profile. What’s in the News for Glenmark Pharmaceuticals Glenmark Pharmaceuticals held an Analyst and Investor Day, providing the market with an updated view of its business priorities, capital allocation plans, and assumptions that can influence how investors assess the stock.
Narrative Update • Jun 23
GLENMARK: US Respiratory And Women’s Health launches Will Support Stronger Outlook
Analysts have lifted their price target for Glenmark Pharmaceuticals from ₹2,129.50 to ₹2,496.50, reflecting updated views on revenue growth assumptions, profit margins, and future P/E expectations. What’s in the News for Glenmark Pharmaceuticals Glenmark Pharmaceuticals held an Analyst and Investor Day, giving the market a closer look at its business priorities and the outlook it shared with institutional stakeholders.
Narrative Update • Jun 07
GLENMARK: US Respiratory And Allergy Approvals Will Support Future Upside
Analysts have maintained Glenmark Pharmaceuticals' fair value estimate at ₹2,735.00, and have updated their assumptions to reflect expectations of 10.47% revenue growth, a 14.62% profit margin, and a higher future P/E of 32.71x. What's in the News Board meeting scheduled for May 29, 2026, at 16:30 IST to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a potential equity dividend for the year.Analysis Article • Jun 06
We Think Glenmark Pharmaceuticals' (NSE:GLENMARK) Healthy Earnings Might Be Conservative
The stock was sluggish on the back of Glenmark Pharmaceuticals Limited's ( NSE:GLENMARK ) recent earnings report. Our...Analysis Article • Jun 02
Is Now The Time To Put Glenmark Pharmaceuticals (NSE:GLENMARK) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • May 14
GLENMARK: US Respiratory And Allergy Approvals Will Drive Future Upside
Narrative Update: Glenmark Pharmaceuticals Analyst Price Target The analyst price target for Glenmark Pharmaceuticals is kept at ₹2,735, with analysts citing updated assumptions for revenue growth at 7.13%, profit margin at 19.60%, and a future P/E of 27.61 as key inputs in their refreshed model. What's in the News BlinkRx added access to RYALTRIS Nasal Spray for seasonal allergic rhinitis patients in the US, following Glenmark Pharmaceuticals Inc., USA’s shift to direct commercialization and distribution.Narrative Update • Apr 29
GLENMARK: Future US Respiratory Launches Will Still Leave Earnings At Risk
Analysts have fine tuned their outlook on Glenmark Pharmaceuticals, with the updated price target now set around ₹1,532. This reflects adjustments to assumptions on revenue growth, profit margins and forward P/E that they view as better aligned with the current fundamentals.Narrative Update • Apr 15
GLENMARK: Future US Respiratory Approvals Will Not Offset Earnings Risk
Analysts have adjusted their fair value estimate for Glenmark Pharmaceuticals slightly lower from ₹1,555.42 to ₹1,531.86, citing updated assumptions around revenue growth, profit margins, and future P/E valuation. What's in the News Received final U.S. FDA approval for Progesterone Vaginal Inserts, 100 mg, deemed bioequivalent and therapeutically equivalent to Endometrin Vaginal Inserts, 100 mg, with the reference market showing approximately US$59.2m in annual sales for the 12 months ending February 2026 (IQVIA via company announcement).Narrative Update • Apr 01
GLENMARK: Future Diabetes Launches Will Not Offset Slower Revenue Trajectory
Analysts have nudged their fair value estimate for Glenmark Pharmaceuticals to ₹1,555 from ₹1,542, reflecting updated assumptions around a slightly lower discount rate, more conservative revenue growth and profit margin inputs, and a higher future P/E multiple. What's in the News Launch of GLIPIQ (semaglutide) in India for Type 2 diabetes, with vial and pre-filled pen formats aimed at making GLP-1 therapy more affordable and accessible after approval by the Central Drugs Standard Control Organization (CDSCO) following a Phase III study in Indian patients (Key Developments).Narrative Update • Mar 17
GLENMARK: Upcoming US Respiratory Launch Will Support Future Upside
Analysts have kept Glenmark Pharmaceuticals' fair value estimate steady at ₹2,735, reflecting slightly updated assumptions on revenue growth, profit margin, and future P/E that currently offset each other in their price target models. What's in the News Glenmark Specialty SA received final U.S. FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, which is rated bioequivalent and therapeutically equivalent to FloVent HFA 44 mcg of GlaxoSmithKline (Product-Related Announcements).Narrative Update • Mar 03
GLENMARK: European Allergy Drug Rollout Will Support Future Upside
Analysts have kept their ₹2,735 price target for Glenmark Pharmaceuticals unchanged, citing small revisions to revenue growth, profit margin, and future P/E assumptions that offset each other in their updated model. What's in the News AcuCort AB and Glenmark Pharmaceuticals signed a commercial agreement for Zeqmelit covering Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine, replacing a prior letter of intent and finalising commercial terms for these markets (Key Developments).Narrative Update • Feb 17
GLENMARK: COPD Launches And Europe Expansion Will Drive Future Upside
Analysts have kept their price target for Glenmark Pharmaceuticals steady at ₹2,735. They cited slightly lower assumed revenue growth, an improved profit margin outlook, and a modestly reduced discount rate and future P/E multiple as the key factors behind maintaining their fair value estimate.Narrative Update • Feb 03
GLENMARK: Slower Revenue Outlook Will Outweigh Benefits From New Product Launches
Analysts have adjusted their price target on Glenmark Pharmaceuticals slightly, citing updated assumptions for revenue growth, profit margins, and forward P/E that keep their fair value estimate at ₹1,542.37. What's in the News AcuCort and Glenmark signed a commercial agreement for Zeqmelit covering Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine.Narrative Update • Jan 20
GLENMARK: Slower Revenue Outlook Will Offset Benefits From New Respiratory Launches
Analysts have nudged their fair value estimate for Glenmark Pharmaceuticals from ₹1,500 to about ₹1,542, reflecting updated assumptions around revenue growth, profit margins and a lower forward P/E multiple in their models. What's in the News A board meeting is scheduled on Nov 14, 2025 to consider and approve unaudited financial results for the second quarter and half year ended Sep 30, 2025, along with other matters (company filing).Narrative Update • Jan 06
GLENMARK: Regulatory Clearance And New Respiratory Launches Will Shape Steady Margin Outlook
Analysts have nudged their fair value estimate for Glenmark Pharmaceuticals to ₹2,129.50 from ₹2,112.00, reflecting updated assumptions around slightly higher revenue growth of about 4.40% and a profit margin outlook of roughly 18.52%, along with a modestly adjusted future P/E multiple. What's in the News Received an Establishment Inspection Report with Voluntary Action Indicated status from the U.S. FDA for the Monroe, North Carolina formulations plant, clearing the way to restart commercial manufacturing at the facility (company announcement).Narrative Update • Dec 16
GLENMARK: Margin Expansion And COPD Breakthrough Will Drive Future Upside
Analysts have lowered their price target for Glenmark Pharmaceuticals to ₹2,735 from ₹2,934, citing a more moderate revenue growth outlook and expectations of lower future valuation multiples, partly offset by anticipated improvements in profit margins. What's in the News The company received an Establishment Inspection Report with Voluntary Action Indicated status from the U.S. FDA for the Monroe, North Carolina formulations facility, paving the way to restart commercial manufacturing (company announcement).Narrative Update • Dec 02
GLENMARK: Recent Regulatory Progress And Product Launches Will Balance Near-Term Margins
Analysts have adjusted their fair value estimate for Glenmark Pharmaceuticals slightly downward from ₹2,128.58 to ₹2,112.00. This revision is due to marginally lower expectations for revenue growth and profit margins moving forward.Analysis Article • Nov 19
Glenmark Pharmaceuticals Limited Just Beat Revenue By 16%: Here's What Analysts Think Will Happen Next
As you might know, Glenmark Pharmaceuticals Limited ( NSE:GLENMARK ) recently reported its second-quarter numbers...Narrative Update • Nov 18
GLENMARK: Improving Margins And Trial Expansion Will Drive Shares Higher
Glenmark Pharmaceuticals: Analyst Price Target Update Analysts have revised Glenmark Pharmaceuticals' fair value estimate downward from ₹2,246.45 to ₹2,128.58. This revision is due to slower projected revenue growth, which is partially offset by improved profit margins and a lower future price-to-earnings ratio.Analysis Article • Nov 12
Getting In Cheap On Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Might Be Difficult
Glenmark Pharmaceuticals Limited's ( NSE:GLENMARK ) price-to-sales (or "P/S") ratio of 3.8x may not look like an...Analysis Article • Sep 20
Here's Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Is The Least Of Shareholders' Concerns
Key Insights Glenmark Pharmaceuticals to hold its Annual General Meeting on 26th of September Salary of ₹149.9m is part...Narrative Update • Sep 03
Branded Portfolio Expansion Will Drive Global Emerging Market Access
The modest upward revision in Glenmark Pharmaceuticals' consensus price target to ₹2246 appears primarily driven by a slightly higher future P/E multiple, with revenue growth forecasts largely unchanged. What's in the News Glenmark announced the upcoming US launch of Micafungin for Injection, entering a $60.7 million annual market with a bioequivalent product to Astellas Pharma's Mycamine.
New Narrative • Dec 10
Lirafit Launch And BeiGene Partnership Set To Accelerate Revenue Growth And Market Share
Upcoming biosimilar launches and strategic oncology partnerships could significantly boost Glenmark's revenue and market share in India.Shareholder Returns
| GLENMARK | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.02% | -0.7% | -0.5% |
| 1Y | 19.6% | 15.2% | 1.7% |
Return vs Industry: GLENMARK exceeded the Indian Pharmaceuticals industry which returned 15.2% over the past year.
Return vs Market: GLENMARK exceeded the Indian Market which returned 1.7% over the past year.
Price Volatility
| GLENMARK volatility | |
|---|---|
| GLENMARK Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stable Share Price: GLENMARK has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GLENMARK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 16,946 | Glenn Saldanha | glenmarkpharma.com |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors.
Glenmark Pharmaceuticals Limited Fundamentals Summary
| GLENMARK fundamental statistics | |
|---|---|
| Market cap | ₹654.11b |
| Earnings (TTM) | ₹17.98b |
| Revenue (TTM) | ₹177.37b |
36.4x
P/E Ratio3.7x
P/S RatioIs GLENMARK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLENMARK income statement (TTM) | |
|---|---|
| Revenue | ₹177.37b |
| Cost of Revenue | ₹49.78b |
| Gross Profit | ₹127.59b |
| Other Expenses | ₹109.61b |
| Earnings | ₹17.98b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 63.71 |
| Gross Margin | 71.94% |
| Net Profit Margin | 10.14% |
| Debt/Equity Ratio | 5.6% |
How did GLENMARK perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield4%
Payout RatioDoes GLENMARK pay a reliable dividends?
See GLENMARK dividend history and benchmarks| Glenmark Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | Aug 31 2026 |
| Dividend Pay Date | Oct 11 2026 |
| Days until Ex dividend | 9 days |
| Days until Dividend pay date | 50 days |
Does GLENMARK pay a reliable dividends?
See GLENMARK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 17:25 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Glenmark Pharmaceuticals Limited is covered by 38 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |